A Ph1b Study of Osimertinib + Alisertib or Sapanisertib for Osimertinib-Resistant EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) (Crossover Study)
Latest Information Update: 09 Aug 2023
At a glance
- Drugs Alisertib (Primary) ; Osimertinib (Primary) ; Sapanisertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 03 Aug 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Apr 2022 Status changed from recruiting to active, no longer recruiting.